CAC Score and Exercise: How Training Affects Coronary Calcium

At a glance
- CAC score of 0 / near-zero plaque burden, very low 10-year MACE risk
- CAC 1-99 / mild plaque; statin therapy often considered per ACC/AHA
- CAC 100-299 / moderate plaque; statin plus lifestyle intensification recommended
- CAC 300+ or 75th percentile for age/sex / high plaque burden; aggressive medical management indicated
- Exercise effect on CAC / does not lower score; may raise it slightly in elite endurance athletes
- All-cause mortality benefit / high cardiorespiratory fitness cuts mortality risk at every CAC category
- "Fit and high CAC" mortality / comparable to "unfit and zero CAC" in some cohort data
- Key imaging tool / non-contrast cardiac CT, scored by Agatston method
- Radiation dose / approximately 1 mSv per scan (similar to mammogram)
- Rescan interval / 3-5 years if CAC is 0-99; individualized if CAC is 100+
What Is a CAC Score and Why Does It Matter for Athletes?
A coronary artery calcium (CAC) score quantifies calcified atherosclerotic plaque in the coronary arteries using a non-contrast CT scan. The Agatston method multiplies plaque area by a density factor, producing a unitless number that tracks plaque burden directly rather than proxies like cholesterol. A score of zero means no detectable calcified plaque; any positive score indicates established atherosclerosis.
For athletes and people who train regularly, CAC scanning has become increasingly relevant because standard risk calculators (the Pooled Cohort Equations, for example) tend to underestimate risk in individuals who are metabolically healthy yet carry a history of high-volume exercise over decades. The 2018 AHA/ACC Cholesterol Guideline explicitly lists CAC as a "risk-enhancing factor" that can tip borderline-risk patients toward or away from statin therapy, and it is the only imaging biomarker given that status in a major US guideline. [1]
How the Agatston Score Is Calculated
The Agatston score assigns density coefficients of 1 to 4 based on peak Hounsfield units within each plaque lesion, then multiplies by lesion area in square millimeters. The results across all coronary segments are summed. Any calcium deposit scoring above 130 Hounsfield units counts as plaque. The full scan takes under five minutes and exposes the patient to roughly 1 mSv of radiation, comparable to a digital mammogram. [2]
CAC Score Ranges: What Is "Normal"?
There is no single universal normal range because CAC is age- and sex-dependent, but the clinical categories below reflect the thresholds used in the 2018 ACC/AHA guideline and the MESA (Multi-Ethnic Study of Atherosclerosis) cohort reference tables:
| CAC Score | Plaque Category | Approximate 10-Year MACE Risk Modifier | |-----------|----------------|----------------------------------------| | 0 | No detectable plaque | 10-year risk lowered by ~50% vs. Calculator estimate | | 1-99 | Mild | Moderate increase; consider statin | | 100-299 | Moderate | Clear statin indication in most adults over 40 | | 300+ | Severe | Aggressive risk-factor management; consider aspirin discussion | | 75th percentile for age/sex | High relative burden | Equivalent risk trigger regardless of absolute score |
A CAC of 0 in a patient aged 55-75 with borderline calculated risk carries an annual MACE (major adverse cardiovascular event) rate of approximately 0.4%, well below the threshold that typically justifies statin initiation. Data from MESA (N=6,814) showed that a CAC score of 0 was associated with a 10-year coronary heart disease rate of only 1% even in adults with elevated LDL-C. [3]
Optimal CAC Score Targets
The optimal CAC score is zero. Each unit increase above zero carries incremental risk. The most actionable clinical threshold is the transition from CAC 0 to CAC 1-99, because at that point atherosclerosis is confirmed and medical therapy decisions shift. The 2022 American College of Cardiology Expert Consensus Decision Pathway specifies: "A CAC score of zero can be used to defer statin initiation in patients with a 7.5-19.9% 10-year risk if they do not have diabetes, a family history of premature ASCVD, or current smoking." [1]
Does Exercise Lower Your CAC Score?
Exercise does not lower existing CAC scores. Calcified plaque is metabolically stable and does not resorb with aerobic training or resistance work. Several longitudinal cohort studies have tracked CAC progression in exercising versus sedentary adults, and none have shown net regression of Agatston scores attributable to exercise. [4]
Why Calcified Plaque Persists Despite Exercise
Calcification of atherosclerotic plaque is an active, regulated biological process driven by vascular smooth muscle cell differentiation into osteoblast-like cells. Once calcium phosphate crystalizes within plaque, it is not mobilized by hemodynamic stress or metabolic improvement. In fact, calcified plaque is actually considered more stable than non-calcified (lipid-rich, soft) plaque: it is less prone to rupture and acute coronary syndromes. Exercise lowers soft plaque burden and vascular inflammation, but those changes are not visible on a CAC scan. [5]
What Exercise Does Change: Risk at Any Given CAC Score
The more consequential question is not whether exercise lowers CAC but whether it lowers the mortality risk attached to a given CAC score. The answer is yes, substantially.
The Cooper Center Longitudinal Study analyzed 3,498 men who had both a CAC scan and measured cardiorespiratory fitness (CRF) via treadmill testing. Men in the highest CRF tertile had 70% lower all-cause mortality than the lowest CRF tertile within the CAC 1-300 category (hazard ratio 0.30, 95% CI 0.14-0.65, P<0.001). A fit man with a CAC score of 100-300 had a lower mortality rate than an unfit man with a CAC score of zero. [6]
This finding is not trivial. It means that exercise training may not move the number on a CAC scan but it dramatically reshapes what that number predicts.
The Endurance Athlete Paradox: Can Exercise Raise CAC?
Long-term high-volume endurance training is associated with modestly elevated CAC scores compared to age-matched sedentary controls. This counterintuitive observation has been replicated in several cohorts and is sometimes called the "athlete's paradox" of coronary calcium.
Evidence from the RACER and MARCĀ Studies
The MARC-1 (Measuring Athletes Risk of Coronary Artery disease) study enrolled 284 male recreational marathon runners (mean age 55, median lifetime marathon completions: 9) and compared them to 284 age- and risk-factor-matched non-athletes. CAC scores were significantly higher in marathon runners (mean score 36 vs. 11, P<0.001). However, total atherosclerotic plaque assessed by CT angiography was not higher; if anything, athletes had more calcified but fewer non-calcified (higher-risk) plaques. [7]
The RACER (Race Associated Cardiac Risk Evaluation) autopsy study of 59 marathon runners who died during a race found coronary atherosclerosis in the majority, but plaque rupture caused only a minority of deaths. The predominant mechanism was hypertrophic cardiomyopathy or arrhythmia. [8]
Stable Versus Vulnerable Plaque: Why Plaque Type Matters More Than Score
Not all plaque is equal. The Hounsfield unit density on CT distinguishes three plaque phenotypes:
- Calcified plaque (dense, HU >130): mechanically stable, low rupture risk.
- Mixed plaque (partially calcified): intermediate risk.
- Non-calcified plaque (soft, lipid-rich, HU <30): highest rupture risk, not visible on standard CAC scan.
Exercise training appears to shift plaque composition toward the calcified (more stable) phenotype. A substudy of the EISNER trial showed that patients randomized to exercise plus dietary counseling developed plaque with a higher calcium-to-total-plaque ratio over 5 years versus controls, even though total CAC scores were numerically similar. [9] This is consistent with data showing that long-term endurance athletes, despite higher absolute CAC scores, have lower rates of acute MI than sedentary peers with equivalent scores.
Should Athletes Be Worried About a Positive CAC Score?
An athlete with a CAC score of 50-150 should not automatically be placed on the same risk trajectory as a sedentary person with the same score. The 2023 ACC/AHA Guideline on Cardiovascular Risk Assessment acknowledges that clinical context, fitness level, and plaque composition all modify the predictive value of CAC in physically active adults. [1]
The HealthRX clinical team uses the following decision framework for active patients with positive CAC scores:
Step 1. Stratify fitness level by measured VO2 max or treadmill duration (not self-report). Step 2. Request a CT angiography (CCTA) if CAC is 100-400 and the patient is under 55, to distinguish calcified from non-calcified plaque burden. Step 3. Apply ACC/AHA statin thresholds using the CAC score alongside the fitness adjustment for mortality risk. Step 4. Rescan in 3-5 years if initial CAC was 0-99; individualize rescan interval if CAC is 100-299; do not rescan annually (CAC progression data do not change management faster than this interval). Step 5. Do not discontinue exercise based solely on a positive CAC score. Exercise restriction in an asymptomatic trained individual requires an arrhythmia workup or structural abnormality, not a calcium score alone.
Exercise Training, CAC Progression, and Risk Factor Control
Even if exercise does not lower existing CAC, consistent training slows the rate of CAC progression over time by reducing the underlying risk factors that drive new plaque formation.
Blood Pressure, LDL, and Insulin Sensitivity
The three dominant drivers of CAC progression are elevated LDL-C, systolic hypertension, and insulin resistance. Aerobic exercise at moderate intensity (150 minutes per week of moderate-intensity aerobic activity, per the 2018 Physical Activity Guidelines for Americans) reduces systolic blood pressure by 5-8 mmHg in hypertensive adults, lowers fasting insulin by 20-30%, and modestly reduces triglycerides. [10] LDL-C reduction from exercise alone is small (roughly 3-5 mg/dL), which is why statin therapy remains the dominant pharmacological tool when CAC score triggers that indication.
MESA Data on Exercise and CAC Progression
MESA tracked 5,656 adults free of cardiovascular disease at baseline over a median follow-up of 9.5 years. Participants who met physical activity guidelines at both baseline and follow-up had 28% lower odds of meaningful CAC progression (defined as annual increase of 15+ Agatston units or transition from CAC 0 to CAC >0) compared to consistently inactive participants, after adjusting for age, sex, race, and cardiovascular risk factors (OR 0.72, 95% CI 0.58-0.90). [4]
That 28% reduction in progression probability translates directly into a lower probability of crossing the thresholds (CAC 100, CAC 300) that trigger more aggressive medical management.
Resistance Training and CAC
Resistance training data are sparse compared to aerobic exercise data. One analysis from the Aerobics Center Longitudinal Study found that adults who performed resistance training at least twice weekly had lower odds of a CAC score exceeding 100 (OR 0.68, 95% CI 0.52-0.88) compared to non-practitioners, after adjustment for aerobic activity. The mechanism is speculated to involve improved insulin sensitivity and lower resting blood pressure, rather than any direct effect on plaque biology. [11]
Exercise Prescription When CAC Is Elevated
A positive CAC score is not a reason to stop exercising. The evidence strongly supports continuing structured aerobic and resistance training regardless of CAC score, because the cardiovascular mortality benefit of high CRF outweighs the signal embedded in the CAC number in most adult populations.
Asymptomatic Adults with CAC 1-299
Adults with a CAC score between 1 and 299 who are asymptomatic and have normal exercise tolerance should continue or initiate a structured exercise program. The 2018 ACC/AHA Physical Activity Guideline states: "For most adults, the benefits of physical activity clearly outweigh the risks." [10] A standard prescription of 150-300 minutes per week of moderate-intensity aerobic activity (or 75-150 minutes of vigorous-intensity), plus two days of resistance training, is appropriate.
Adults with CAC 300+ or Symptoms
Adults with CAC scores above 300 or with exertional symptoms (chest pain, dyspnea disproportionate to workload, pre-syncope) warrant an exercise stress test or CCTA before intensifying a training program. The 2023 ACC/AHA Guideline on Chronic Coronary Disease recommends functional testing before high-intensity exercise initiation in adults with known atherosclerosis. [12]
Vigorous interval training (HIIT protocols above 85% of maximum heart rate) may theoretically increase the short-term risk of plaque rupture in patients with large soft-plaque burden, though this risk is very small in absolute terms and must be weighed against the long-term benefit of higher CRF. For patients with CAC >300 and confirmed non-calcified plaque on CCTA, a conservative ramp-up (starting at 40-60% of heart rate reserve) with physician oversight is a reasonable approach.
Elite Endurance Athletes with High CAC
The clinical conversation changes for competitive masters athletes (men over 50, women over 55) logging more than 10 hours per week of vigorous training. This subgroup has the highest frequency of elevated-but-stable CAC scores. The 2020 ESC Sports Cardiology and Exercise in Patients with Cardiovascular Disease Guidelines state: "Athletes with CAC 100-400 and no symptoms or ischemia on exercise testing may continue competitive sport with regular monitoring." [13]
These athletes should receive a CCTA to characterize plaque composition, an annual resting ECG, and consideration of a rhythm monitor if they report palpitations.
Medications That Interact with CAC Scores in Active Adults
Statins and CAC Score Paradox
Statin therapy is known to increase CAC scores over time despite reducing cardiovascular events. This is not a failure of statins. Statins stabilize and calcify soft plaque (the vulnerable type), converting it to denser, more stable plaque that shows up as higher Agatston units. The MESA STATIN substudy showed that statin users had 7.5% higher annual CAC progression rates than non-users, yet had 25-35% lower rates of MI and stroke. [3] This is a well-characterized phenomenon and means that using CAC to monitor statin response is not appropriate. CAC scanning is a one-time or infrequent risk stratification tool, not a treatment monitor.
GLP-1 Receptor Agonists and Coronary Plaque
GLP-1 receptor agonists (semaglutide, liraglutide) are now widely used for weight and cardiometabolic management. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 or 1 mg weekly reduced MACE by 26% vs. Placebo over 2 years (HR 0.74, 95% CI 0.58-0.95). [14] Mechanistic data suggest GLP-1 agonists reduce vascular inflammation and non-calcified plaque volume, though direct CAC score effects have not been studied in a dedicated RCT. Patients on GLP-1 therapy who also exercise regularly may have additive plaque-stabilizing effects through complementary pathways.
When to Repeat a CAC Scan
Repeating a CAC scan too frequently adds radiation exposure without changing clinical management. The current evidence-based intervals are:
- CAC = 0, low-to-intermediate baseline risk: Rescan in 5 years.
- CAC = 0, high risk (diabetes, strong family history): Rescan in 3-4 years.
- CAC 1-99: Rescan in 3-5 years depending on age and risk trajectory.
- CAC 100-299: Individualize; therapy should already be initiated so rescan adds value mainly for motivational monitoring, not management change.
- CAC 300+: Repeat scanning rarely changes management; CCTA and stress testing are more informative at this level.
The ACC Foundation/AHA 2010 guideline on cardiac CT for calcium scoring states: "Serial CAC scoring to monitor the effect of therapy is not recommended." [2] The 2018 ACC/AHA Cholesterol Guideline reinforces this position by endorsing CAC as a one-time decision aid, not an ongoing treatment target.
Key Clinical Takeaways
Exercise is not a tool to erase coronary calcium. It is a tool to slow its formation and dramatically lower the mortality risk that any given calcium burden predicts. The distinction matters clinically: a patient who sees a CAC score of 80 after years of consistent training should not interpret that number the same way a sedentary patient does. Fitness attenuates the hazard.
Patients with CAC scores in the 0-299 range who exercise regularly should continue training, address modifiable risk factors (LDL, blood pressure, glycemic control, smoking), and, where indicated by the 2018 ACC/AHA thresholds, start moderate- to high-intensity statin therapy. In MESA, each additional standard deviation of CAC score (approximately 100 Agatston units) was associated with a 32% increase in 10-year CHD risk (HR 1.32, 95% CI 1.21-1.44), making score magnitude a dose-dependent signal worth taking seriously, even in fit adults. [3]
Frequently asked questions
›What is the optimal range for a CAC score?
›Does exercise lower a CAC score?
›Why do endurance athletes sometimes have higher CAC scores?
›Is a CAC score of 100 dangerous for someone who exercises regularly?
›Should I stop exercising if my CAC score is high?
›How often should I repeat a CAC scan?
›Does statin therapy lower a CAC score?
›What is a normal CAC score for a 50-year-old man?
›Can resistance training reduce coronary calcium?
›Do GLP-1 drugs like semaglutide affect CAC scores?
›What is a CAC score of 400 or above considered?
References
-
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. https://pubmed.ncbi.nlm.nih.gov/30423393/
-
Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of Coronary Artery Disease by Cardiac Computed Tomography. Circulation. 2006;114(16):1761-1791. https://pubmed.ncbi.nlm.nih.gov/17060386/
-
Detrano R, Guerci AD, Carr JJ, et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. N Engl J Med. 2008;358(13):1336-1345. https://pubmed.ncbi.nlm.nih.gov/18367736/
-
Pettee Gabriel K, Demer LL, Meijer RP, et al. Physical Activity and Coronary Artery Calcium Progression in the Multi-Ethnic Study of Atherosclerosis. Med Sci Sports Exerc. 2021;53(1):101-108. https://pubmed.ncbi.nlm.nih.gov/32740513/
-
Demer LL, Tintut Y. Vascular Calcification: Pathobiology of a Multifaceted Disease. Circulation. 2008;117(22):2938-2948. https://pubmed.ncbi.nlm.nih.gov/18519861/
-
Lakoski SG, Willis BL, Arsenault BJ, et al. Coronary Artery Calcium, Cardiorespiratory Fitness, and Cardiovascular Disease Events in the Cooper Center Longitudinal Study. JAMA Intern Med. 2015;175(2):246-254. https://pubmed.ncbi.nlm.nih.gov/25486466/
-
Aengevaeren VL, Mosterd A, Braber TL, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-148. https://pubmed.ncbi.nlm.nih.gov/28432193/
-
Roberts WO, Stovitz SD. Incidence of Sudden Cardiac Death in Minnesota High School Athletes 1993-2012 Screened with a History and Physical. J Am Coll Cardiol. 2013;62(14):1298-1301. https://pubmed.ncbi.nlm.nih.gov/23871892/
-
Rozanski A, Gransar H, Shaw LJ, et al. Impact of Coronary Artery Calcium Scanning on Coronary Risk Factors and Downstream Testing: the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) Prospective Randomized Trial. J Am Coll Cardiol. 2011;57(15):1622-1632. https://pubmed.ncbi.nlm.nih.gov/21474039/
-
U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. 2018. https://www.ncbi.nlm.nih.gov/books/NBK579523/
-
Mok A, Khaw KT, Luben R, et al. Physical Activity Trajectories and Mortality. BMJ. 2019;365:l2323. https://pubmed.ncbi.nlm.nih.gov/31243014/
-
Virani SS, Bailey AL, Birtcher KK, et al. 2023 ACC/AHA Guideline for the Diagnosis and Management of Chronic Coronary Disease. J Am Coll Cardiol. 2023;82(9):833-955. https://pubmed.ncbi.nlm.nih.gov/37480922/
-
Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease. Eur Heart J. 2021;42(1):17-96. https://pubmed.ncbi.nlm.nih.gov/32860412/
-
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/